193 related articles for article (PubMed ID: 1991815)
1. Correlation between serum osteocalcin and 24,25-dihydroxyvitamin D levels in Paget's disease of bone.
Castro-Errecaborde N; de la Piedra C; Rapado A; Alvarez-Arroyo MV; Torres R; Traba ML
J Clin Endocrinol Metab; 1991 Feb; 72(2):462-6. PubMed ID: 1991815
[TBL] [Abstract][Full Text] [Related]
2. Osteocalcin and urinary hydroxyproline/creatinine ratio in the differential diagnosis of primary hyperparathyroidism and hypercalcaemia of malignancy.
de la Piedra C; Toural V; Rapado A
Scand J Clin Lab Invest; 1987 Oct; 47(6):587-92. PubMed ID: 3499657
[TBL] [Abstract][Full Text] [Related]
3. Alterations in vitamin D metabolites during treatment of Paget's disease of bone with calcitonin or etidronate.
Devlin RD; Gutteridge DH; Prince RL; Retallack RW; Worth GK
J Bone Miner Res; 1990 Nov; 5(11):1121-6. PubMed ID: 2125401
[TBL] [Abstract][Full Text] [Related]
4. Osteocalcin and bone remodelling in Paget's disease of bone, primary hyperparathyroidism, hypercalcaemia of malignancy and involutional osteoporosis.
Torres R; de la Piedra C; Rapado A
Scand J Clin Lab Invest; 1989 May; 49(3):279-85. PubMed ID: 2787049
[TBL] [Abstract][Full Text] [Related]
5. [The correlation between the serum levels of osteocalcin and 24,25-dihydroxyvitamin D in Paget's disease of bone].
Castro Errecarborde N; de la Piedra Gordo C; Rapado Errazti A
An Med Interna; 1990 Jun; 7(6):286-90. PubMed ID: 2102732
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D status in Paget's bone disease. Effects of calcitonin therapy.
Nunziata V; Giannattasio R; di Giovanni G; Lettera AM; Nunziata CA
Clin Orthop Relat Res; 1993 Aug; (293):366-71. PubMed ID: 8339504
[TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of serum tartrate-resistant acid phosphatase in Paget's disease of bone: correlation with other biochemical markers of bone remodelling.
Torres R; de la Piedra C; Rapado A
Calcif Tissue Int; 1991 Jul; 49(1):14-6. PubMed ID: 1893290
[TBL] [Abstract][Full Text] [Related]
8. [Decrease of the coefficient of intestinal calcium absorption with normal blood levels of 1,25-dihydroxyvitamin D and decreasing levels of 24,25-dihydroxyvitamin D in Paget's disease of bone].
Traba ML; Climent P; Rapado A; de la Piedra C; Díaz Curiel M
Rev Clin Esp; 1986 Nov; 179(8):401-3. PubMed ID: 3494277
[No Abstract] [Full Text] [Related]
9. Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone.
Delmas PD; Demiaux B; Malaval L; Chapuy MC; Meunier PJ
Calcif Tissue Int; 1986 Jan; 38(1):60-1. PubMed ID: 3079654
[TBL] [Abstract][Full Text] [Related]
10. Age-related changes in vitamin D metabolites, osteocalcin, alkaline phosphatase and parathyrin in normal Chinese women in Taipei.
Tsai KS; Chen JS; Hwang KM; Chieng PU; Su CT
J Formos Med Assoc; 1991 Nov; 90(11):1033-7. PubMed ID: 1687046
[TBL] [Abstract][Full Text] [Related]
11. Comparison of serum osteocalcin with total and bone specific alkaline phosphatase and urinary hydroxyproline:creatinine ratio in patients with Paget's disease of bone.
Kaddam IM; Iqbal SJ; Holland S; Wong M; Manning D
Ann Clin Biochem; 1994 Jul; 31 ( Pt 4)():327-30. PubMed ID: 7979096
[TBL] [Abstract][Full Text] [Related]
12. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
[TBL] [Abstract][Full Text] [Related]
13. Abnormal vitamin D metabolism in Paget's disease of bone.
Guillard-Cumming DF; Beard DJ; Douglas DL; Johnson SK; Lawson-Matthew PJ; Russell RG; Kanis JA
Clin Endocrinol (Oxf); 1985 Apr; 22(4):559-66. PubMed ID: 3872746
[TBL] [Abstract][Full Text] [Related]
14. Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease.
Singer FR; Clemens TL; Eusebio RA; Bekker PJ
J Clin Endocrinol Metab; 1998 Jun; 83(6):1906-10. PubMed ID: 9626117
[TBL] [Abstract][Full Text] [Related]
15. Binding of serum osteocalcin to hydroxyapatite in Paget's disease of bone.
Torres R; de la Piedra C; Rapado A
Bone Miner; 1991 Jul; 14(1):55-65. PubMed ID: 1868269
[TBL] [Abstract][Full Text] [Related]
16. Bone turnover in rats treated with 1,25-dihydroxyvitamin D3, 25-hydroxyvitamin D3 or 24,25-dihydroxyvitamin D3.
Mortensen BM; Gautvik KM; Gordeladze JO
Biosci Rep; 1993 Feb; 13(1):27-39. PubMed ID: 8392394
[TBL] [Abstract][Full Text] [Related]
17. Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment.
Papapoulos SE; Frolich M; Mudde AH; Harinck HI; vd Berg H; Bijvoet OL
J Clin Endocrinol Metab; 1987 Jul; 65(1):89-94. PubMed ID: 3495547
[TBL] [Abstract][Full Text] [Related]
18. Serum osteocalcin and vitamin D in postmenopausal diabetic azotemics.
Lu KC; Shieh SD; Chyr SH; Lin SH; Li BL; Diang LK; Chen WQ; Lin YF
Diabetes Res; 1993; 22(3):97-104. PubMed ID: 8076446
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid function in Paget's disease of bone.
Siris ES; Clemens TP; McMahon D; Gordon A; Jacobs TP; Canfield RE
J Bone Miner Res; 1989 Feb; 4(1):75-9. PubMed ID: 2718781
[TBL] [Abstract][Full Text] [Related]
20. Long-term elevation of 1,25-dihydroxyvitamin D after short-term intravenous administration of pamidronate (aminohydroxypropylidene bisphosphonate, APD) in Paget's disease of bone.
Devlin RD; Retallack RW; Fenton AJ; Grill V; Gutteridge DH; Kent GN; Prince RL; Worth GK
J Bone Miner Res; 1994 Jan; 9(1):81-5. PubMed ID: 8154313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
